ALIMERA SCIENCES, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2022-12-08: Form 8-K; Period of report 2022-12-07; Description 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 8.01 Other Events; Details 1.01.
- 2022-11-14: Form 8-K; Period of report 2022-11-10; Description 2.02 Results of Operations and Financial Condition; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure; Details 2.02.
- 2022-11-04: Form 8-K; Period of report 2022-11-02; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2022-07-27: Form 8-K; Period of report 2022-07-27; Description 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2022-12-08 | 8-K | 2022-12-07 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 8.01 Other Events | 1.01 Entry into a Definitive Material Agreement. 2.03 The information disclosed in Item 1.01 above is incorporated herein by reference. 8.01 On December 8, 2022, Alimera issued a press release announcing the Amendment. | alim-20221207x8k.htm |
| 2022-11-14 | 8-K | 2022-11-10 | 2.02 Results of Operations and Financial Condition; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure | 2.02 On November 14, 2022, Alimera Sciences, Inc. (“Alimera”) issued a press release regarding its results of operations and financial condition for the three and nine months ended September 30, 2022 as well as a corporate update. 5.02 As previously reported, J. Philip Jones resigned as Chief Financial Officer of Alimera Sciences, Inc. (the “Company”), effective November 28, 2022. 7.01 The conference call and webcast, and the press release, include or will include non-GAAP financial measures. | alim-20221110x8k.htm |
| 2022-11-04 | 8-K | 2022-11-02 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On November 2, 2022, J. Philip Jones resigned as Chief Financial Officer of Alimera Sciences, Inc. (the “Company”), effective November 28, 2022. | c602-20221102x8k.htm |
| 2022-07-27 | 8-K | 2022-07-27 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 2.02 On July 27, 2022, Alimera Sciences, Inc. (“Alimera”) issued a press release regarding its results of operations and financial condition for the three and six months ended June 30, 2022 as well as a corporate update. 7.01 The conference call and webcast, and the press release, include or will include a non-GAAP financial measure, Adjusted EBITDA. | alim-20220727x8k.htm |
| 2022-07-13 | 8-K | 2022-07-12 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On July 12, 2022, Alimera Sciences, Inc. (the “Company”) held its 2022 annual meeting of stockholders (the “Annual Meeting”). | alim-20220712x8k.htm |
| 2022-06-07 | 8-K | 2022-06-07 | 7.01 Regulation FD Disclosure | 7.01 Richard S. Eiswirth, Jr., the President and Chief Executive Officer of Alimera Sciences, Inc. (“Alimera”), will present on behalf of Alimera at the upcoming LD Micro conference that begins on June 7, 2022. | alim-20220607x8k.htm |
| 2022-05-09 | 8-K | 2022-05-09 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 2.02 On May 9, 2022, Alimera Sciences, Inc. (“Alimera”) issued a press release regarding its results of operations and financial condition for the first quarter ended March 31, 2022 as well as a corporate update. 7.01 The conference call and webcast, and the press release, include or will include a non-GAAP financial measure, Adjusted EBITDA. | alim-20220509x8k.htm |
| 2022-02-28 | 8-K | 2022-02-22 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 1.01 Entry into a Definitive Material Agreement. 2.03 The information disclosed in Item 1.01 above is incorporated herein by reference. | alim-20220222x8k.htm |
| 2022-02-24 | 8-K | 2022-02-24 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 2.02 On February 24, 2022, Alimera Sciences, Inc. (“Alimera”) issued a press release regarding its results of operations and financial condition for the fourth quarter and full year ended December 31, 2021 as well as a corporate update. 7.01 The conference call and webcast, and the press release, include or will include a non-GAAP financial measure, Adjusted EBITDA. | alim-20220224x8k.htm |